MCP Server For Financial Data by EODHD Learn more

Ligand Pharmaceuticals Incorporated icon

Ligand Pharmaceuticals Incorporated (LGND NASDAQ) stock market data APIs

$196.4521 1.66(0.9%)
as of February 2, 2026
Try our APIs with free plan!

Ligand Pharmaceuticals Incorporated Financial Data Overview

Price chart is built with Anychart

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Prev. Close 196.4521
Open 196.5387
High 197.0416
Low 190.8365
52 wk Range 93.58-212.49
Market Cap 3 896 M
P/E Ratio 86.8114
Shares Outstanding 19 682 K
Revenue 251 M
EPS 3.09
Beta 1.038

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


ETFs with Ligand Pharmaceuticals Incorporated (top by weight)

Ticker
100-day Price Change
Weight
HELX.US Franklin Genomic Advancements ETF
2.7 (7.94%)
3.09
AFSC.US abrdn Focused U.S. Small Cap Active ETF
1.58 (5.15%)
3.01
ETLI.F Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF
0.24 (2.15%)
3.01
ETLI.XETRA L&G Pharma Breakthrough UCITS ETF
0.41 (3.62%)
3.01
PJP.US Invesco Dynamic Pharmaceuticals ETF
12.41 (13.09%)
2.59
PSCH.US Invesco S&P SmallCap Health Care ETF
1.86 (4.34%)
2.06
XPH.US SPDR® S&P Pharmaceuticals ETF
8.42 (17.31%)
1.97
WBSIX.US WILLIAM BLAIR SMALL CAP GROWTH FUND CLASS I
4.5 (14.42%)
1.88

* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Ligand Pharmaceuticals Incorporated data using free add-ons & libraries


Get Ligand Pharmaceuticals Incorporated Fundamental Data

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated Fundamental data includes:

  • Net Revenue: 251 M
  • EBITDA: 63 034 K
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Ligand Pharmaceuticals Incorporated Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2025-11-06
  • EPS/Forecast: 1.93
GET THE PACKAGE

Get Ligand Pharmaceuticals Incorporated End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Ligand Pharmaceuticals Incorporated News

Get Ligand Pharmaceuticals Incorporated fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat

Send the request

Leave your email and our team will contact you ASAP.